Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 102 | 115 | +13 |
| Shares | 60.3M | 73.1M | +12.8M (+21.3%) |
| Value | $141.8M | $208.5M | +$66.7M (+47.1%) |
New holders (33)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (20)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Millennium Management LLC | 1,425,776 | $3.35M |
| ExodusPoint Capital Management, LP | 334,197 | $785.0K |
| HRT Financial LP | 289,018 | $679.0K |
| Qube Research & Technologies Ltd | 191,483 | $450.0K |
| Williams Jones Wealth Management, LLC. | 101,300 | $238.0K |
| Gsa Capital Partners LLP | 80,000 | $188.0K |
| DAFNA Capital Management LLC | 75,400 | $177.0K |
| LMR Partners LLP | 72,194 | $170.0K |
| California Public Employees Retirement System | 48,400 | $114.0K |
| Balyasny Asset Management LLC | 36,162 | $85.0K |
| Schonfeld Strategic Advisors LLC | 33,574 | $78.0K |
| Diametric Capital, LP | 26,712 | $63.0K |
| Jefferies Group LLC | 24,400 | $57.3K |
| Capstone Investment Advisors, LLC | 21,090 | $50.0K |
| Sciencast Management LP | 18,076 | $45.0K |
| Prelude Capital Management, LLC | 17,529 | $41.0K |
| Maven Securities LTD | 13,185 | $30.0K |
| Gluskin Sheff & Assoc Inc | 10,000 | $24.0K |
| Integrated Wealth Concepts LLC | 10,000 | $24.0K |
| Eudaimonia Partners, LLC | 500 | $1.00K |